Anupam Rama
Stock Analyst at JP Morgan
(3.33)
# 979
Out of 4,876 analysts
265
Total ratings
41.86%
Success rate
4.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Overweight | $21 → $25 | $7.34 | +240.83% | 5 | May 29, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $63 → $66 | $22.29 | +196.10% | 8 | May 22, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $169 → $84 | $17.23 | +387.52% | 12 | May 20, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.56 | +514.04% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $37.13 | +215.11% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $126.71 | +45.21% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $45.12 | +10.82% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $9.29 | +341.33% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $36.19 | +40.92% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $4.81 | +128.69% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $6.48 | +424.69% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $42 | $23.38 | +79.64% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $77 → $71 | $23.29 | +204.85% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $18.40 | +193.48% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $15.13 | +190.81% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $9.46 | +90.27% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $10.50 | +109.52% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.74 | +135.48% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $5.69 | +198.77% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.73 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $28.49 | +40.40% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $79.16 | +57.91% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.72 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $46.99 | +44.71% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $9.28 | +7.76% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.36 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.31 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.45 | +430.61% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.36 | +2,434.50% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.78 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.39 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $7.95 | +3,044.65% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.33 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $33.91 | +71.04% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $10.73 | +11.84% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.31 | +596.80% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $55.22 | -0.39% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.26 | +2,122.22% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $33.65 | +60.48% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.38 | +11,896.80% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $10.05 | +168.66% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.02 | +299.20% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $318.25 | -56.95% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.78 | +715.90% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $6.50 | +638.46% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.94 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.81 | +2,119.48% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.83 | +3,503.17% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $49.55 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.78 | - | 2 | Jul 21, 2017 |
Cogent Biosciences
May 29, 2025
Maintains: Overweight
Price Target: $21 → $25
Current: $7.34
Upside: +240.83%
IDEAYA Biosciences
May 22, 2025
Maintains: Overweight
Price Target: $63 → $66
Current: $22.29
Upside: +196.10%
Sarepta Therapeutics
May 20, 2025
Maintains: Overweight
Price Target: $169 → $84
Current: $17.23
Upside: +387.52%
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.56
Upside: +514.04%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $37.13
Upside: +215.11%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $126.71
Upside: +45.21%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $45.12
Upside: +10.82%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $9.29
Upside: +341.33%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $36.19
Upside: +40.92%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.81
Upside: +128.69%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.48
Upside: +424.69%
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $23.38
Upside: +79.64%
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $23.29
Upside: +204.85%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $18.40
Upside: +193.48%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $15.13
Upside: +190.81%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $9.46
Upside: +90.27%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $10.50
Upside: +109.52%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $12.74
Upside: +135.48%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $5.69
Upside: +198.77%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $9.73
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $28.49
Upside: +40.40%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $79.16
Upside: +57.91%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $46.99
Upside: +44.71%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $9.28
Upside: +7.76%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.36
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.31
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.45
Upside: +430.61%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.36
Upside: +2,434.50%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.78
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.39
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $7.95
Upside: +3,044.65%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $33.91
Upside: +71.04%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $10.73
Upside: +11.84%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.31
Upside: +596.80%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $55.22
Upside: -0.39%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.26
Upside: +2,122.22%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $33.65
Upside: +60.48%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.38
Upside: +11,896.80%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $10.05
Upside: +168.66%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.02
Upside: +299.20%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $318.25
Upside: -56.95%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.78
Upside: +715.90%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $6.50
Upside: +638.46%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $9.94
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.81
Upside: +2,119.48%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.83
Upside: +3,503.17%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $49.55
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.78
Upside: -